We read with interest the article by Tré-Hardy et al., 1 who monitored the anti-SARS-CoV-2
(severe acute respiratory syndrome coronavirus 2) spike antibodies levels using the
LIAISON® SARS-CoV-2 IgG kit in naïve recipients of mRNA-1273 vaccine. Although it was
found that these antibodies persisted up to 3 months after vaccination, a significant decrease
of their serum levels could be observed in some seronegative participants, thus supporting
the opportunity to administer an additional vaccine dose in specific subgroups of recipients …